Abstract
Membranous nephropathy is a common cause of primary nephrotic syndrome, yet it can be particularly vexing to treat due to its extended duration and uncertainties about the implications of a partial remission. Ten years ago, the phospholipase A2 receptor (PLA2R) was identified as the major target
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have